Overview

The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

Status:
Terminated
Trial end date:
2016-10-29
Target enrollment:
Participant gender:
Summary
This is a prospective,multicentre study to compare the efficacy, safety, tolerability and relapse of FK506 versus CTX in the treatment of severe Focal Segmental Glomerulosclerosis (FSGS).
Phase:
N/A
Details
Lead Sponsor:
Nanjing University School of Medicine
Treatments:
Cyclophosphamide
Tacrolimus